Physician profile
Douglas Linfert
NPI 1710032255
$4,539.47
in general payments reported to CMS, 2019-2025
23 companies · $294 in 2025
The $294 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193 · 2020: $46.09 · 2021: $145 · 2022: $3,820 · 2023: $41.30 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $335.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,575.00 | 2022 | |
| Fresenius USA Marketing, INC. | $170.52 | 2022-2023 | Velphoro |
| Galderma Laboratories, L.P. | $145.16 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $137.23 | 2019-2025 | Jynarque, Voyxact |
| Baxter Healthcare | $94.01 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $92.78 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $56.36 | 2019-2025 | Tavneos |
| Genzyme Corporation | $39.70 | 2025 | |
| Calliditas Therapeutics US INC. | $39.62 | 2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $36.01 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $24.05 | 2020 | |
| Vifor Pharma, INC. | $23.51 | 2019 | |
| Mallinckrodt Enterprises LLC | $20.67 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.66 | 2025 | Jardiance |
| Shire North American Group INC | $19.25 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $18.65 | 2025 | |
| Alexion Pharmaceuticals, INC. | $14.51 | 2019 | |
| Opko Pharmaceuticals, LLC | $12.78 | 2019 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Linfert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.